The older antihistamines are not gentler. They are the ones with the safety record

The second-generation antihistamines are meaningfully better than the first-generation ones, and the difference is not mainly about how well they treat allergy — it is about what else they do. A task force of the Global Allergy and Asthma European Network reviewed the first-generation drugs and concluded that they should no longer be available over the counter without prescription, on the grounds that newer non-sedating alternatives with superior risk-benefit ratios are widely available at competitive prices [s1]. Those older drugs are still sold off the shelf in most countries, often as sleep aids and cold remedies.

What the older drugs do besides treat allergy

The GA2LEN task force assessed the unwanted effects of first-generation H1-antihistamines by reviewing the Medline and Embase literature and auditing US media coverage from 1996 to 2008 of accidents and fatal adverse events in which these drugs were implicated [s1].

Their finding starts from a perception problem: first-generation H1-antihistamines are generally regarded as safe by laypeople and healthcare professionals alike, because they have been in use for so long [s1]. All of them are sedating [s1]. Beyond drowsiness, the review reports that they reduce REM sleep, impair learning and reduce work efficiency [s1]. They have been implicated in civil aviation, motor vehicle and boating accidents; in deaths from accidental or intentional overdose in infants and young children; and in suicide in teenagers and adults [s1]. Some are cardiotoxic in overdose [s1].

The reduced REM sleep, impaired learning and reduced work efficiency the task force describes are central nervous system effects rather than incidental discomforts, which is why they show up in the accident and overdose record alongside the drowsiness [s1].

The task force's stated aim was consumer protection — bringing the dangers of indiscriminate over-the-counter use to the attention of regulators, physicians and the public [s1]. That aim has been only partly achieved. The drugs remain widely available.

On symptom relief, the newer drugs are not interchangeable either

A network meta-analysis pooled 18 randomised controlled trials with 9,419 participants to rank oral H1 antihistamines against each other for allergic rhinitis, using symptom score reductions and ranking treatments by surface under the cumulative ranking curve, or SUCRA [s2].

Every antihistamine treatment studied outperformed placebo, on total symptom score and on each individual symptom score [s2]. Beyond that, they separated. Rupatadine 20 mg and rupatadine 10 mg ranked highest for total symptom score (SUCRA 99.7% and 76.3%), nasal congestion (96.4%, 76.4%), rhinorrhoea (96.6%, 74.6%) and ocular symptoms (97.2%, 88.8%) [s2]. For nasal itching the top ranks were rupatadine 20 mg and levocetirizine 5 mg (84.8%, 83.4%), and for sneezing, levocetirizine 5 mg and rupatadine 20 mg (95.4%, 87.3%) [s2].

Loratadine 10 mg ranked lowest of every active treatment, on every symptom score [s2]. That is the one most people have heard of.

How much weight that ranking carries

Less than the precision of the numbers suggests. SUCRA values are rankings derived from a network of indirect comparisons, not measured differences between drugs — a treatment can rank first on a narrow and uncertain margin. The review included 18 trials, which is a modest evidence base for ranking a whole drug class, and network meta-analyses inherit whatever heterogeneity exists in how the constituent trials measured symptoms [s2]. The finding to take from it is the shape rather than the order: all of these drugs beat placebo, and they are not equivalent to each other [s2].

Availability also varies by country in ways the ranking ignores. Rupatadine is not marketed everywhere, and the drugs stocked on a pharmacy shelf are not the same set the meta-analysis compared.

Where antihistamines sit in guideline treatment

The ARIA guidelines, developed with the Global Allergy and Asthma European Network using the GRADE approach, cover oral and topical medications, allergen-specific immunotherapy and complementary treatments for allergic rhinitis, which the guideline describes as affecting 10% to 20% of the population and roughly 500 million people globally [s3]. The panel built evidence profiles for each recommendation and weighed benefits, harms, burden, patient preferences and resource use [s3].

The structural point worth carrying over from a guideline of that kind is that oral antihistamines are one option among several with different profiles, not the definitionally correct first move, and that the choice is expected to involve patient preference alongside evidence [s3].

The practical summary

Two questions are usually collapsed into one. "Are newer antihistamines better?" on safety has a clear answer: the first-generation drugs carry sedation, cognitive impairment and overdose risks that a specialist task force considered serious enough to argue for taking them off open sale [s1]. On efficacy the answer is narrower: all of the oral antihistamines studied beat placebo, they differ from each other by amounts that are ranked rather than precisely measured, and the most familiar brand-name molecule ranked last among active treatments in the largest network comparison available [s2].

This article describes published evidence about a drug class. It is not advice about which product to use, and any change to a medication regimen belongs with a pharmacist or clinician who knows the rest of it.

Sources

• Risk of first-generation H1-antihistamines: a GA2LEN position paper — Allergy, 2010-02-08
• Efficacy of different oral H1 antihistamine treatments on allergic rhinitis: a systematic review and network meta-analysis of randomized controlled trials — Brazilian Journal of Otorhinolaryngology, 2023-04-07
• Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision — Journal of Allergy and Clinical Immunology, 2010-09-04